Dasatinib in Treating Patients With Early Chronic Phase Chronic Myelogenous Leukemia
Status:
Active, not recruiting
Trial end date:
2022-11-30
Target enrollment:
Participant gender:
Summary
This randomized phase II trial studies how well dasatinib works in treating patients with
early chronic phase chronic myelogenous leukemia. Dasatinib may stop the growth of cancer
cells by blocking some of the enzymes needed for cell growth.
Phase:
Phase 2
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborators:
Bristol-Myers Squibb National Cancer Institute (NCI)